Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. OMER
OMER logo

OMER Should I Buy

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Should You Buy Omeros Corp (OMER) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion
Hold
Latest Price
10.280
1 Day change
6.59%
52 Week Range
17.650
Analysis Updated At
2026/06/12
Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.

OMER is not a good buy right now for a beginner long-term investor with $50,000-$100,000 who wants to act now rather than wait. The stock is weak in pre-market, lacks a fresh catalyst, and the technical setup is still fragile despite some supportive options positioning. I would not buy it today.

Technical Analysis

OMER is in a soft short-term downtrend. Pre-market price is 9.91, down 2.65%, below the pivot level of 10.304 and approaching support at 9.704. MACD histogram is negative at -0.0738 and still contracting, which signals weakening momentum. RSI_6 at 36.323 is neutral-to-weak, not oversold enough to justify an aggressive entry. Moving averages are converging, suggesting indecision rather than a clear uptrend. The stock trend model also leans bearish, with a 60% probability of further downside over the next day, week, and month.

Options Data

Bullish
Open Interest Put-Call Ratio
Bearish
Option Volume Put-Call Ratio

Options sentiment is mixed but slightly constructive on positioning. The open interest put-call ratio of 0.61 shows more calls than puts in open interest, while the volume put-call ratio of 1.97 shows heavier put trading today, indicating near-term caution or hedging. Implied volatility is very elevated at 122.09, above historical volatility of 49.73, so traders are pricing in a large move. Option volume today is also much higher than the 30-day average, which signals strong activity, but not necessarily bullish conviction.

Technical Summary

StrongSellSellNeutralBuyStrongBuydotted line Image
Sell
6
Buy
7

Positive Catalysts

  • ["Hedge funds are buying, with reported buying increasing sharply over the last quarter.", "Options open interest leans toward calls, which suggests some longer-dated bullish positioning.", "High options activity could support a sharp move if a catalyst appears."]

Neutral/Negative Catalysts

  • ["No news in the recent week, so there is no clear event-driven catalyst.", "Pre-market price is down 2.65%, showing immediate weakness.", "MACD is negative and deteriorating.", "The stock trend model points to downside over the next day, week, and month.", "Insiders are neutral, with no meaningful buying signal.", "SwingMax shows no recent entry signal and AI Stock Pick shows no signal today.", "No recent congress trading data is available.", "Financial snapshot data was unavailable, so there is no supportive latest-quarter growth evidence."]

Financial Performance

Latest quarter financial data was not available due to an error in the provided snapshot, so I cannot confirm revenue or earnings growth trends. Because there is no latest-quarter season or financial breakdown, there is no visible fundamental acceleration to support a long-term buy decision.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

No analyst rating or price target change data was provided, so there is no evidence here of a recent upward revision trend. Based on the available information, Wall Street pros appear split at best: hedge-fund accumulation is a positive, but the lack of news, the weak technicals, and the absence of fresh analyst upgrades argue against a strong bullish consensus.

Wall Street analysts forecast OMER stock price to rise
4 Analyst Rating
Wall Street analysts forecast OMER stock price to rise
3 Buy
1 Hold
0 Sell
Strong Buy
Current: 9.640
sliders
Low
36
Averages
43.67
High
55
Current: 9.640
sliders
Low
36
Averages
43.67
High
55
H.C. Wainwright
Brandon Folkes
maintain
$20 -> $40
AI Analysis
2026-01-08
Reason
H.C. Wainwright
Brandon Folkes
Price Target
$20 -> $40
AI Analysis
2026-01-08
maintain
Reason
H.C. Wainwright analyst Brandon Folkes raised the firm's price target on Omeros to $40 from $20 and keeps a Buy rating on the shares. The firm cites the approval of Yartemlea for hematopoietic stem cell transplant-associated thrombotic microangiopathy for the target boost. The analyst views the approval as a "critical inflection point" for Omeros.
H.C. Wainwright
H.C. Wainwright
Buy
maintain
$20
2025-12-24
Reason
H.C. Wainwright
H.C. Wainwright
Price Target
$20
2025-12-24
maintain
Buy
Reason
H.C. Wainwright reiterated a Buy rating and $20 price target on Omeros following the FDA approval of Yartemlea for hematopoietic stem cell transplant-associated thrombotic microangiopathy. The firm sees the Yartemlea approval as a "significant validation" of Omeros value. H.C. Wainwright's current model assumed an 80% probability of success for Yartemlea in the U.S., and pricing of $150K per patient.
Unlock Full Analyst Thesis, Get the complete breakdown of rating reason for OMER
Unlock Now

People Also Watch